CANSF WILLOW BIOSCIENCES INC
- 0.065450
- 0.0000000.00%
WILLOW BIOSCIENCES INC News
Willow Biosciences GAAP EPS of -C$0.10, Revenue of C$1.17M
Press Release: WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF PR Newswire SUNNYVALE, Calif., March 28, 2024 Completed the reorganization of the
WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC
WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Company Exploring CBG Production Signals New Era Of Commercial Success In Synthetic Biology
Biotech company Willow Biosciences Inc. (TSX:WLLW) (OTCQB:CANSF) generated nearly $1.3 million in revenues in 2023, increasing approximately 60% over the period.Dr. Chris Savile, president and CEO of
Stocks in Play: Willow Biosciences Inc.
This Precision-Fermentation Company Achieves Q3 Record Revenue And Strategic Milestones In Business Expansion
Willow Biosciences Inc. (TSX:WLLW) (OTCQB:CANSF) has reported its financial and operating results for the third quarter ending September 30, 2023, showcasing record revenue and substantial progress in
Aurora Cannabis And Willow Biosciences Resolve Patent Clash
Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) announced Tuesday that it had successfully completed a confidential settlement resolving an ongoing patent litigation with Willow Biosciences Inc. (OTCQB:C
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
CALGARY, AB, Oct. 10, 2023 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of
Cannabis Stock Gainers And Losers From August 25, 2023
GAINERS:Clever Leaves Holdings (NASDAQ:CLVR) shares closed up 2433.26% at $4.57Skye Bioscience (OTC:SKYE) shares closed up 35.00% at $0.01InnoCan Pharma (OTC:INNPF) shares closed up 34.04% at $0.26Ind
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM
Announces commercial focus on BioOxiTM bio-oxidation platform as part of targeted alignment on nearer-term and larger revenue opportunities Reduces number of board members as part of geographic transition as a San
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
SUNNYVALE, Calif., Aug. 21, 2023 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB:CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and
Cannabis Stock Movers For August 18, 2023
GAINERS:Australis Capital (OTC:AUSAF) shares closed up 900.00% at $0.001Target Group (OTC:CBDY) shares closed up 63.64% at $0.011606 (OTC:CBDW) shares closed up 44.68% at $0.03Blueberries Medical (OTC
Willow Biosciences Reports Q2 Results
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
New partnerships and contracts expected to bring in over $1 million in near-term R&D/milestone revenue and generate long term commercial revenue SUNNYVALE, Calif., Aug. 8, 2023 /CNW/ - Willow Biosciences
KALSEC AND WILLOW BIOSCIENCES TO DEVELOP NOVEL ENZYME FOR PRODUCTION OF AN ADVANCED BEVERAGE INGREDIENT
Rapid success of first collaboration leads to partnership on high-value specialty ingredient Enzyme development expected to enable commercial-scale production in 2024 KALAMAZOO, Mich. and MOUNTAIN VIEW, Calif., May 23,
Press Release: WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
MOUNTAIN VIEW, Calif., May 12, 2023 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on May 12, 2023 (the "Meeting"). A total of 57,318,575 common shares, representing approximately 46.329% of the Company's issued and outstanding shares were represented at the meeting.
Willow Biosciences Q1 FY23 Revenue Grows To $203K, Still In Development Stage And On 'A Solid Trajectory'
Willow Biosciences Inc. (OTCQB:CANSF) (TSX:WLLW) released its financial and operating results for the three months ended March 31, 2023, revealing revenue of CA$274,000Â ($203,000) compared to no re
Analysis
Price Target
No Data
